Company: INDP
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001493152-25-021759
Chunk: 50

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 8
Chunk 50
---
    of common stock comprised of (i) 10,927 commitment
    shares, and (ii) up to 346,215 shares
    of common stock reserved for issuance and sale to Yorkville under the SEPA. The Form S-1 was declared effective on February 13,
    2025. During the first nine months of 2025, the Company sold and issued 89,902 shares
    of common stock under the SEPA for aggregate net proceeds of approximately $1.74
    million, after deducting offering expenses in the amount of approximately $0.1 million.

    d.
     
    On
    June 1, 2022, the Company entered into an ATM Agreement which was amended on September 1, 2022 with a sales agent, pursuant to which
    the Company may offer and sell, from time to time through the sales agent, shares of the Company’s common stock. The issuance
    and sale of common stock by the Company under the ATM Agreement is being made pursuant to the Company’s effective
    “shelf” registration statement on Form S-3 filed with the SEC on August 13, 2025 and declared effective on August 20,
    2025. During September 2025 the Company sold 520,000 shares
    of the Company’s common stock for aggregate net proceeds of approximately $2.25 million, after deducting issuance expenses in the amount of approximately $0.1 million. The
    Company’s ability to issue shares under the shelf registration statement on Form S-3 is limited by General Instruction I.B.6
    to Form S-3.

    F-10

NOTE
7: CONVERTIBLE PROMISSORY NOTES

In
June 2025, the Company entered into securities purchase agreements with certain investors, including the chief executive officer of the
Company, for the offering in a private placement of convertible promissory notes (the “Notes”) in the aggregate principal
amount of approximately $5.7 million and warrants to purchase shares of common stock.

The
Notes bore interest at the rate of 6%
per year and mature on July
28, 2026. The Notes were convertible, together with accrued interest, into shares of the Company’s common stock on the
date which was the earlier of (i) the date that is 30 days from the effectiveness of a reverse split effected by the Company on
Nasdaq (i.e